Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, will issue its preliminary results for the twelve-month period ended 30 June 2016 on Monday 26 September 2016.
Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Finance Director, will host a presentation and conference call for analysts on the day of results at the offices of Panmure Gordon, One New Change, London, EC4M 9AF.